

Publisher: Blackwell Publishing
E-ISSN: 1097-0142|121|17|2871-2873
ISSN: 0008-543X
Source: Cancer, Vol.121, Iss.17, 2015-09, pp. : 2871-2873
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Horizons expanded for sunitinib in GIST
Inpharma, Vol. 1, Iss. 1602, 2007-01 ,pp. :


PharmacoEconomics and Outcomes News, Vol. 1, Iss. 652, 2012-01 ,pp. :


Sunitinib gets the gist in imatinib-resistance
Inpharma, Vol. 1, Iss. 1491, 2005-01 ,pp. :


Adjuvant imatinib worth the cost in GIST patients
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 617, 2010-01 ,pp. :


Imatinib for priority review by US FDA for GIST recurrence.
Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. :